<VariationArchive VariationID="6006" VariationName="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter)" VariationType="Duplication" Accession="VCV000006006" Version="17" RecordType="classified" NumberOfSubmissions="7" NumberOfSubmitters="5" DateLastUpdated="2024-07-15" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21045" VariationID="6006">
      <GeneList>
        <Gene Symbol="SLC25A13" FullName="solute carrier family 25 member 13" GeneID="10165" HGNC_ID="HGNC:10983" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7q21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96120220" stop="96322098" display_start="96120220" display_stop="96322098" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95749531" stop="95951458" display_start="95749531" display_stop="95951458" Strand="-" />
          </Location>
          <OMIM>603859</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter)</Name>
      <CanonicalSPDI>NC_000007.14:96121696:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>7q21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96121696" stop="96121697" display_start="96121696" display_stop="96121697" variantLength="1" positionVCF="96121696" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95751008" stop="95751009" display_start="95751008" display_stop="95751009" variantLength="1" positionVCF="95751008" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>Y600*</ProteinChange>
      <ProteinChange>Y601*</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.2" sequenceAccession="NM_014251" sequenceVersion="2" change="c.1799dup">
            <Expression>NM_014251.2:c.1799dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.95751009dup" Assembly="GRCh37">
            <Expression>NC_000007.13:g.95751009dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.96121697dup" Assembly="GRCh38">
            <Expression>NC_000007.14:g.96121697dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012247.2" sequenceAccession="NG_012247" sequenceVersion="2" change="g.205451dup">
            <Expression>NG_012247.2:g.205451dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160210.2" sequenceAccession="NM_001160210" sequenceVersion="2" change="c.1802dup">
            <Expression>NM_001160210.2:c.1802dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001153682.1" sequenceAccession="NP_001153682" sequenceVersion="1" change="p.Tyr601Ter">
            <Expression>NP_001153682.1:p.Tyr601Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.3" sequenceAccession="NM_014251" sequenceVersion="3" change="c.1799dup" MANESelect="true">
            <Expression>NM_014251.3:c.1799dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055066.1" sequenceAccession="NP_055066" sequenceVersion="1" change="p.Tyr600Ter">
            <Expression>NP_055066.1:p.Tyr600Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_027662.2" sequenceAccession="NR_027662" sequenceVersion="2" change="n.1825dup">
            <Expression>NR_027662.2:n.1825dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA253675" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="603859.0006" DB="OMIM" />
        <XRef Type="rs" ID="80338726" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00002" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00004" Source="Exome Aggregation Consortium (ExAC)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter) AND Neonatal intrahepatic cholestasis due to citrin deficiency" Accession="RCV000006375" Version="5">
        <ClassifiedConditionList TraitSetID="1662">
          <ClassifiedCondition DB="MedGen" ID="C1853942">Neonatal intrahepatic cholestasis due to citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter) AND Citrullinemia type II" Accession="RCV000006374" Version="6">
        <ClassifiedConditionList TraitSetID="1661">
          <ClassifiedCondition DB="MedGen" ID="C1863844">Citrullinemia type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2001-05-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter) AND Citrin deficiency" Accession="RCV001060497" Version="8">
        <ClassifiedConditionList TraitSetID="9638">
          <ClassifiedCondition DB="MedGen" ID="C1997910">Citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter) AND Citrullinemia" Accession="RCV001831516" Version="2">
        <ClassifiedConditionList TraitSetID="64881">
          <ClassifiedCondition DB="MedGen" ID="C0175683">Citrullinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-09-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1799dup (p.Tyr600Ter) AND Citrullinemia, type II, adult-onset" Accession="RCV003472984" Version="2">
        <ClassifiedConditionList TraitSetID="65850">
          <ClassifiedCondition DB="MedGen" ID="CN295299">Citrullinemia, type II, adult-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-03-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-12" NumberOfSubmissions="7" NumberOfSubmitters="5" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11153906</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11343052</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11793471</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301360</ID>
          <ID Source="BookShelf">NBK1181</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="64881" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="54673" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia</ElementValue>
                <XRef ID="MONDO:0015991" DB="MONDO" />
                <XRef ID="398680004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Citrullinuria</ElementValue>
                <XRef ID="HP:0032397" DB="Human Phenotype Ontology" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CTNL1</ElementValue>
                <XRef ID="GTR000558544" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16522" />
                <XRef ID="16522" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="187" DB="Orphanet" />
              <XRef ID="C0175683" DB="MedGen" />
              <XRef ID="MONDO:0015991" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS215700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0032397" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9638" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6541" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrin deficiency</ElementValue>
                <XRef ID="MONDO:0016602" DB="MONDO" />
                <XRef ID="429735007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="20661" />
                <XRef ID="20661" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247582" DB="Orphanet" />
              <XRef ID="C1997910" DB="MedGen" />
              <XRef ID="MONDO:0016602" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1661" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="973" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Citrullinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Citrullinemia type II</ElementValue>
                <XRef ID="Citrullinemia+Type+II/1652" DB="Genetic Alliance" />
                <XRef ID="MONDO:0016603" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10215" />
                <XRef ID="10215" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="C1863844" DB="MedGen" />
              <XRef ID="MONDO:0016603" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1662" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4809" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal intrahepatic cholestasis caused by citrin deficiency</ElementValue>
                <XRef ID="Citrin+Deficiency/1648" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Neonatal intrahepatic cholestasis due to citrin deficiency</ElementValue>
                <XRef ID="MONDO:0011601" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NICCD</ElementValue>
                <XRef Type="MIM" ID="605814" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10214" />
                <XRef ID="10214" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247598" DB="Orphanet" />
              <XRef ID="C1853942" DB="MedGen" />
              <XRef ID="MONDO:0011601" DB="MONDO" />
              <XRef Type="MIM" ID="605814" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65850" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55843" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia, type II, adult-onset</ElementValue>
                <XRef ID="MONDO:0011326" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTLN2</ElementValue>
                <XRef Type="MIM" ID="603471" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia_II_Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Citrin Deficiency, Citrullinemia II, Urea Cycle Disorder, 2012</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="CN295299" DB="MedGen" />
              <XRef ID="MONDO:0011326" DB="MONDO" />
              <XRef Type="MIM" ID="603471" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="26557" SubmissionDate="2013-09-24" DateLastUpdated="2013-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603859.0006_CITRULLINEMIA, TYPE II, NEONATAL-ONSET" title="SLC25A13, 1-BP INS, NT1800_CITRULLINEMIA, TYPE II, NEONATAL-ONSET" />
        <ClinVarAccession Accession="SCV000026557" DateUpdated="2013-09-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2001-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Yasuda et al. (2000) identified 2 patients with adult-onset type II citrullinemia (603471) who were compound heterozygous for the IVS11+1G-A mutation (603859.0002) and a 1-bp insertion at nucleotide 1800, predicting premature termination (Y200X) of the C terminus of the SLC25A13 gene.</Attribute>
              <Citation>
                <ID Source="PubMed">11153906</ID>
              </Citation>
              <XRef DB="OMIM" ID="603471" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tazawa et al. (2001) identified the 1800ins1 mutation in compound heterozygous state with the S225X mutation (603859.0004) in a child with neonatal-onset type II citrullinemia (605814). Liver histology showed fatty tissue without evidence of giant cell hepatitis, the usual finding in most forms of transient neonatal jaundice.</Attribute>
              <Citation>
                <ID Source="PubMed">11343052</ID>
              </Citation>
              <XRef DB="OMIM" ID="605814" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <Name>SLC25A13, 1-BP INS, NT1800</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, NT1800</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603859.0006" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">CITRULLINEMIA, TYPE II, NEONATAL-ONSET</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="26556" SubmissionDate="2013-09-24" DateLastUpdated="2013-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603859.0006_CITRULLINEMIA, TYPE II, ADULT-ONSET" title="SLC25A13, 1-BP INS, NT1800_CITRULLINEMIA, TYPE II, ADULT-ONSET" />
        <ClinVarAccession Accession="SCV000026556" DateUpdated="2013-09-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2001-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Yasuda et al. (2000) identified 2 patients with adult-onset type II citrullinemia (603471) who were compound heterozygous for the IVS11+1G-A mutation (603859.0002) and a 1-bp insertion at nucleotide 1800, predicting premature termination (Y200X) of the C terminus of the SLC25A13 gene.</Attribute>
              <Citation>
                <ID Source="PubMed">11153906</ID>
              </Citation>
              <XRef DB="OMIM" ID="603471" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tazawa et al. (2001) identified the 1800ins1 mutation in compound heterozygous state with the S225X mutation (603859.0004) in a child with neonatal-onset type II citrullinemia (605814). Liver histology showed fatty tissue without evidence of giant cell hepatitis, the usual finding in most forms of transient neonatal jaundice.</Attribute>
              <Citation>
                <ID Source="PubMed">11343052</ID>
              </Citation>
              <XRef DB="OMIM" ID="605814" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <Name>SLC25A13, 1-BP INS, NT1800</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, NT1800</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603859.0006" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CITRULLINEMIA, TYPE II, ADULT-ONSET</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292627" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000007.13:g.95751009dupT|OMIM:605814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163571" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95751009dupT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2390690" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="3233115|MedGen:C1997910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001225190" DateUpdated="2024-02-14" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11153906</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11793471</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11153906</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11343052</ID>
          </Citation>
          <Comment>This variant is present in population databases (rs80338726, gnomAD 0.02%). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the SLC25A13 protein. Other variant(s) that disrupt this region (p.Arg605*, p.Glu601*) have been observed in individuals with SLC25A13-related conditions (PMID: 11153906, 11793471). This suggests that this may be a clinically significant region of the protein. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. ClinVar contains an entry for this variant (Variation ID: 6006). This variant is also known as Mutation VI, 1800ins1. This premature translational stop signal has been observed in individuals with citrin deficiency (PMID: 11153906, 11343052). This sequence change creates a premature translational stop signal (p.Tyr600*) in the SLC25A13 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 76 amino acid(s) of the SLC25A13 protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95751008_95751009insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1997910" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4076407" SubmissionDate="2022-02-09" DateLastUpdated="2022-02-13" DateCreated="2022-02-13">
        <ClinVarSubmissionID localKey="NM_014251.3:c.1799dup|Citrullinemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002079361" DateUpdated="2022-02-13" DateCreated="2022-02-13" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.1799dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Citrullinemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="41256" SubmissionDate="2013-01-08" DateLastUpdated="2022-10-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="NM_014251.2:c.1799dupA_NBK1181" title="NM_014251.2:c.1799dupA and Citrin Deficiency" />
        <ClinVarAccession Accession="SCV000041256" DateUpdated="2022-10-01" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">11153906</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="PubMed">20301360</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="BookShelf">NBK1181</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <Purpose>Assert pathogenicity</Purpose>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80338726" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.1799dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1863844" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7854554" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_014251.3:c.1799dup|OMIM:603471" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004201635" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.1799dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="26556" TraitType="Disease" MappingType="Name" MappingValue="CITRULLINEMIA, TYPE II, ADULT-ONSET" MappingRef="Preferred">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4076407" TraitType="Disease" MappingType="Name" MappingValue="Citrullinemia" MappingRef="Preferred">
        <MedGen CUI="C0175683" Name="Citrullinemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2390690" TraitType="Disease" MappingType="XRef" MappingValue="C1997910" MappingRef="MedGen">
        <MedGen CUI="C1997910" Name="Citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7854554" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="26557" TraitType="Disease" MappingType="Name" MappingValue="CITRULLINEMIA, TYPE II, NEONATAL-ONSET" MappingRef="Alternate">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292627" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="41256" TraitType="Disease" MappingType="XRef" MappingValue="C1863844" MappingRef="MedGen">
        <MedGen CUI="C1863844" Name="Citrullinemia type II" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-05-28">SCV001523973</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

